Skip to main content
SpringerLink
Log in

Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Antiphospholipid syndrome (APS) is associated with pregnancy complications such as recurrent early fetal loss (RFL), fetal death, preeclampsia (PE), and intrauterine growth restriction (obstetric APS/OAPS). Other clinical manifestations are venous and/or arterial thromboses (thrombotic APS/TAPS). The data of 37 pregnancies with OAPS and 37 pregnancies with TAPS were analyzed and compared. Overall, the most frequent APS antibodies (aPl) were LA as well as “triple-positivity”; LA antibodies were significantly more frequent in women with TAPS (67.6 % TAPS vs. 29.7 % OAPS, p < 0.010), whereas “triple-positivity” was significantly more seen in women with OAPS (40.5 % OAPS vs. 13.5 % TAPS, p < 0.010). Adequate therapy has been administered in nearly all pregnancies with TAPS, whereas in 18.9 % of pregnancies with OPS, no therapy has been given at all. One woman in OAPS and four women in TAPS were treated with plasmapheresis and immunoadsorption. There was no significant association between adverse obstetric outcome and therapy. The most frequent pregnancy complications were RFL in the OAPS group (32.4 vs. 13.5 % in TAPS) and PE in the TAPS group (18.9 % in OAPS and TAPS, respectively). The data of our study showed that pregnancies with OAPS and TAPS have a similar rate of pregnancy complications. However, pregnancies with OAPS tend to have rather RFL. Although we were not able to reveal a significant association with adverse obstetric outcome, it seems that the current adequate therapy for APS in pregnancy, consisting of LDA and LMWH, might rather prevent the development of RFL. Additionally, it might be considered to divide the obstetric APS into obstetric APS with early pregnancy complications and obstetric APS with late pregnancy complications. The division into two groups of obstetric APS might facilitate the choice of additional therapy in these women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306

    Article  CAS  PubMed  Google Scholar 

  2. Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernández OM et al (2011) Obstetric antiphospholipid syndrome. Autoimmun Rev 10:669–673

    Article  Google Scholar 

  3. Asherson RA, Cervera R (2014) The antiphospholipid syndrome: multiple faces beyond the classical presentation. J Autoimmun 48-49:20–25

    Article  CAS  Google Scholar 

  4. Gómez-Puerta JA, Cervera R (2014) Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 48–49:20–25

    Article  PubMed  CAS  Google Scholar 

  5. Comarmond C, Cacoub P (2013) Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 12:752–757

    Article  CAS  PubMed  Google Scholar 

  6. Erkan D, Aguiar CL, Andrade D et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13:685–696

    Article  CAS  PubMed  Google Scholar 

  7. Carrera-Marín A, Romay-Penabad Z, Papalardo E et al (2012) C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 21:1497–1505

    Article  PubMed  CAS  Google Scholar 

  8. De Groot PG, Urbanus RT (2015) Antiphospholipid syndrome—not a noninflammatory disease. Semin Thromb Hemost 41:607–614

    Article  PubMed  CAS  Google Scholar 

  9. Girardi G, Berman J, Redecha P et al (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112:1644–1654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Holers VM, Girardi G, Mo L et al (2002) Complement C3 activation is required antiphospholipid antibody induced fetal loss. J Exp Med 195:211–220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cavazzana I, Manuela N, Irene C et al (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28:160–164

    Article  PubMed  CAS  Google Scholar 

  12. Meroni PL, Raschi E, Grossi C et al (2012) Obstetric and vascular APS: same autoantibodies but different disease? Lupus 21:108–710

    Article  Google Scholar 

  13. Alijotas-Reig J, Vilardell-Tarrès M (2010) Is obstetric antiphospholipid syndrome a primary nonthrombotic proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? Obstet Gynecol Surv 65:39–45

    Article  PubMed  Google Scholar 

  14. Branch W, Obstetric Task Force (2011) Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies.13th April 2010. Lupus 20:158–164

    Article  PubMed  Google Scholar 

  15. Levy RA, Jesús GR, Jesús NR (2010) Obstetric antiphospholipid syndrome: still a challenge. Lupus 19:457–459

    Article  CAS  PubMed  Google Scholar 

  16. Alijotas-Reig J (2005) Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 125:187–189

    Article  Google Scholar 

  17. De Jesus GR, Agmon-Levin N, Andrade CA et al (2014) International Congress on Antiphospholipid Antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev 13:795–813

    Article  PubMed  Google Scholar 

  18. D’Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N (2014) Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 13:901–908

    Article  PubMed  Google Scholar 

  19. American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Obstetrics (2011) ACOG Practice Bulletin No. 118: antiphospholipid syndrome. Obstet Gynecol 117:192–199

    Article  Google Scholar 

  20. Tranquilli AL et al (2013) The definition of severe and early-onset preeclampsia. Statements from the international society for the study of hypertension in pregnancy (ISSHP). Pregnancy Hypertens 3:44–47

  21. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31

  22. Clark EA, Silver RM, Branch DW (2007) Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep 9:219–225

    Article  CAS  PubMed  Google Scholar 

  23. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027

    Article  PubMed  Google Scholar 

  24. Branch DW, Andres R, Digre KB, Rote NS, Scott JR (1989) The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 73:541–545

    CAS  PubMed  Google Scholar 

  25. Milliez J, Lelong F, Bayani N et al (1991) The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation. Am J Obstet Gynecol 165:51–56

    Article  CAS  PubMed  Google Scholar 

  26. Moddley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG (1995) The association of antiphospholipid antibodies with severe early-onset preeclampsia. S Afr Med J 85:105–107

    Google Scholar 

  27. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, EUROAPS Study Group Collaborators et al (2015) The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14:387–395

    Article  PubMed  Google Scholar 

  28. Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64

    Article  CAS  PubMed  Google Scholar 

  29. Raymond D, Peterson E (2011) A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 66:497–506

    Article  PubMed  Google Scholar 

  30. Hernández-Díaz S, Toh S, Cnattingius S (2009) Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 338:1–5

    Article  Google Scholar 

  31. Wikstrom AK, Larson A, Eriksson UJ et al (2007) Placental growth factor and soluble fms-like tyrosine kinase-1 in early onset and late-onset preeclampsia. Obstet Gynecol 109:1368–1374

    Article  PubMed  Google Scholar 

  32. Stepan H, Unversucht A, Wessel N et al (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49:818–824

    Article  CAS  PubMed  Google Scholar 

  33. Oudejans CB, van Dijk M, Oosterkamp M et al (2007) Genetics of preeclampsia: paradigm shifts. Hum Genet 120:607–612

    Article  PubMed  Google Scholar 

  34. Huppertz B (2008) Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51:970–975

    Article  CAS  PubMed  Google Scholar 

  35. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ (2014) Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 210:66–67

    Article  PubMed  Google Scholar 

  36. Stark MW, Clark L, Craver RD (2014) Histologic differences in placentas of preeclamptic/eclamptic gestations by birthweight, placental weight, and time of onset. Pediatr Dev Pathol 17:181–189

    Article  PubMed  Google Scholar 

  37. Salafia CM, Pezzulo JC, Ghidini A et al (1998) Clinical correlations of patterns of placental pathology in preterm preeclampsia. Placenta 19:67–72

    Article  CAS  PubMed  Google Scholar 

  38. Goswami D, Tannetta DA, Magee LA et al (2006) Excess syncytiotrophoblast microparticle shedding is a feature of early-onset preeclampsia, but not normotensive intrauterine growth restriction. Placenta 27:56–61

    Article  CAS  PubMed  Google Scholar 

  39. Buurma A, Cohen D, Veraar K et al (2012) Preeclampsia is characterized by placental complement dysregulation. Hypertension 60(5):1332–1337

    Article  CAS  PubMed  Google Scholar 

  40. Harmon AC, Cornelius DC, Amaral LM et al (2016) The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) 130:409–419

    Article  CAS  Google Scholar 

  41. Østensen M, Andreoli L, Brucato A et al (2015) State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 14:376–386

    Article  PubMed  Google Scholar 

  42. Viall CA, Chamley LW (2015) Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 14:446–471

    Article  CAS  PubMed  Google Scholar 

  43. Salafia C, Cowchock F (1997) Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 14:435–441

    Article  CAS  PubMed  Google Scholar 

  44. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM (2004) Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 25:642–648

    Article  PubMed  CAS  Google Scholar 

  45. Branch DW, Khamashta MA (2003) Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Am J Obstet Gynecol 101:1333–1344

    Google Scholar 

  46. Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044

    Article  CAS  PubMed  Google Scholar 

  47. Heilmann L, von Tempelhoff GF, Pollow K (2003) Antiphospholipid syndrome in obstetrics. Clin Appl Thrombosis Hemostasis 9:143–150

    Article  Google Scholar 

  48. Heilmann L, Schorch M, Hahn T et al (2008) Pregnancy outcome in women with antiphospholipid antibodies: report of a retrospective study. Semin Thromb Hemost 34(8):794–802

    Article  CAS  PubMed  Google Scholar 

  49. Blank M, Shoenfeld Y (2010) Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clin Rev Allergy Immunol 38:141–147

    Article  CAS  PubMed  Google Scholar 

  50. Galarza-Maldonado C, Kourilovitch MR, Perez-Fernandez OM et al (2012) Obstetric antiphospholipid syndrome. Autoimmun Rev 11:288–295

    Article  CAS  PubMed  Google Scholar 

  51. Levy RA, dos Santos FC, de Jesus GR, de Jesus NR (2015) Antiphospholipid antibodies and antiphospholipid syndrome during pregnancy: diagnostic concepts. Front Immunol 6:205

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW (1994) Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 83:372–377

    CAS  PubMed  Google Scholar 

  53. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR (1992) Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80:614–620

    CAS  PubMed  Google Scholar 

  54. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR (1996) A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14:131–136

    CAS  PubMed  Google Scholar 

  55. De Carolis S, Botta A, Santucci S et al (2012) Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 21:776–778

    Article  PubMed  Google Scholar 

  56. Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:A299–A304

    Article  PubMed  Google Scholar 

  57. Ruffatti A, Tonello M, Visentin MS et al (2011) Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 50:1684–1689

    Article  CAS  Google Scholar 

  58. Sawhney N, Patel MK, Schachter M, Hughes AD (1997) Inhibition of proliferation by heparin and expression of p53 in cultured human vascular smooth muscle cells. J Hum Hypertens 11:611–614

    Article  CAS  PubMed  Google Scholar 

  59. Kohno M, Yokokawa K, Yasunari K et al (1998) Heparin inhibits human coronary artery smooth muscle cell migration. Metabolism 47:1065–1069

    Article  CAS  PubMed  Google Scholar 

  60. Dilley RJ, Nataatmadja MI (1998) Heparin inhibits mesenteric vascular hypertrophy in angiotensin II-infusion hypertension in rats. Cardiovasc Res 38:247–255

    Article  CAS  PubMed  Google Scholar 

  61. Empson M, Lassere M, Craig JC, Scott JR (2002) Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99:135–144

    PubMed  Google Scholar 

  62. Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17

    Article  CAS  PubMed  Google Scholar 

  63. Scoble T, Wijetilleka S, Khamashta MA (2011) Management of refractory anti-phospholipid syndrome. Autoimmun Rev 10:669–673

    Article  PubMed  Google Scholar 

  64. Andreoli L, Bazzani C, Taraborelli M et al (2010) Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 10:51–54

    Article  PubMed  Google Scholar 

  65. Bramham K, Thomas M, Nelson-Piercy C et al (2011) First trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117:6948–6951

    Article  CAS  PubMed  Google Scholar 

  66. Laskin CA, Bombardier C, Hannah ME et al (1997) Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 17(337):148–153

    Article  Google Scholar 

  67. Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis 68:238–241

    Article  CAS  PubMed  Google Scholar 

  68. Rand JH, Wu XX, Quinn AS et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 18(115):2292–2299

    Article  CAS  Google Scholar 

  69. Albert CR, Schlesinger WJ, Viall CA et al (2014) Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 71:154–164

    Article  CAS  PubMed  Google Scholar 

  70. Marchetti T, Ruffatti A, Wuillemin C, de Moerloose P, Cohen M (2014) Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 12:910–920

    Article  CAS  PubMed  Google Scholar 

  71. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 30(376):1498–1509

    Article  CAS  Google Scholar 

  72. Mekinian A, Lazzaroni MG, Kuzenko A et al (2015) The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 14:498–502

    Article  CAS  PubMed  Google Scholar 

  73. De Carolis S, Botta A, Salvi S et al (2015) Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev 14:760–762

    Article  PubMed  CAS  Google Scholar 

  74. Belizna C (2015) Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 14:358–62

    Article  CAS  PubMed  Google Scholar 

  75. Mekinian A, Costedoat-Chalumeau N, Masseau A et al (2015) Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev 14:23–29

    Article  CAS  PubMed  Google Scholar 

  76. Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ (2016) The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 214(273):e1–e8

    Google Scholar 

  77. Sciascia S, Branch DW, Levy RA et al (2016) The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 27(115):285–290

    Google Scholar 

  78. Al Marzooqi A, Leone A, Al Saleh J, Khamashta M (2016) Current status and future prospects for the treatment of antiphospholipid syndrome. Expert Rev Clin Immunol 3:1–9

    Google Scholar 

  79. Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367:2015–2025

    Article  CAS  PubMed  Google Scholar 

  80. Guidelli GM, Tenti S, Pascarelli NA et al (2015) Granulomatosis with polyangitis and intravenous immunoglobulins: a case series and review of the literature. Autoimmun Rev 14:659–664

    Article  PubMed  Google Scholar 

  81. Sher G, Matzner W, Feinman M et al (1998) The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol 40:74–82

    Article  CAS  PubMed  Google Scholar 

  82. Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A (2016) Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature. Autoimmun Rev 15:226–235

    Article  CAS  PubMed  Google Scholar 

  83. Branch DW, Peaceman AM, Druzin M et al (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182:122–127

    Article  CAS  PubMed  Google Scholar 

  84. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS (2003) Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 51:139–148

    CAS  Google Scholar 

  85. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V (2012) Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 16(72):773–788

    Article  Google Scholar 

  86. Morton S, Thangaratinam S (2013) Statins in pregnancy. Curr Opin Obstet Gynecol 25:433–440

    Article  PubMed  Google Scholar 

  87. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C (2012) Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm 18:1519–1530

    Article  CAS  Google Scholar 

  88. Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu’u-Lino TJ (2016) Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth 20(16):117

    Article  Google Scholar 

  89. Costantine MM, Cleary K, Hebert MF et al (2016) Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 214:720.e1–720.e17

    Article  CAS  Google Scholar 

  90. Lefkou E, Mamopoulos A, Fragakis N et al (2014) Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension 63:e118–e119

    Article  CAS  PubMed  Google Scholar 

  91. Ruffatti A, Marson P, Pengo V et al (2007) Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6:196–202

    Article  PubMed  Google Scholar 

  92. Ruffatti A, Favaro M, Hoxha A et al (2016) Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J Reprod Immunol 29(115):14–19

    Article  CAS  Google Scholar 

  93. Ruffatti A, Favaro M, Brucato A et al (2015) Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfus Apher Sci 53:269–278

    Article  PubMed  Google Scholar 

  94. Bontadi A, Ruffatti A, Marson P et al (2012) Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 27:200–204

    Article  PubMed  Google Scholar 

  95. Kobayashi S, Tamura N, Tsuda H, Mokuno C, Hashimoto H, Hirose S (1992) Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis 51(3):399–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Nakanishi I, Fujita T, Shinohara K et al (1998) Treatment with immunoadsorbent plasmapheresis in a pregnant woman with antiphospholipid syndrome (in Japanese). J Osaka Soc Dialysis Therapy 16:55–58

    Google Scholar 

  97. Nakamura Y, Yoshida K, Itoh S et al (1999) Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 41:307–311

    Article  CAS  PubMed  Google Scholar 

  98. Bortolati M, Marson P, Chiarelli S et al (2009) Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 13(2):157–160

    Article  PubMed  Google Scholar 

  99. El-Haieg DO, Zanati MF, El-Foual FM (2007) Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 99:236–241

    Article  CAS  PubMed  Google Scholar 

  100. Frampton G, Cameron JS, Thom M, Jones S, Raftery M (1987) Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 31:1023–1024

    Article  Google Scholar 

  101. Schwartz ML (1986) Possible role for exchange plasmapheresis with fresh frozen plasma for maternal indications in selected cases of preeclampsia and eclampsia. Obstet Gynecol 68:136–139

    CAS  PubMed  Google Scholar 

  102. Martin JN, Perry KG, Roberts WE, Norman PF, Files JC, Blake PG, Morrison JC, Wiser WL (1994) Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome. J Clin Apher 9:155–161

    Article  PubMed  Google Scholar 

  103. d’Apice AJ, Reti LL, Pepperell RJ, Fairley KF, Kincaid-Smith P (1980) Treatment of severe pre-eclampsia by plasma exchange. Aust N Z J Obstet Gynaecol 20:231–235

    Article  PubMed  Google Scholar 

  104. Tincani A, Rebaioli CB, Andreoli L, Lojacono A, Motta M (2009) Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 11:70–76

    Article  CAS  PubMed  Google Scholar 

  105. Mekinian A, Lachassinne E, Nicaise-Roland P et al (2013) European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 72:217–222

    Article  PubMed  Google Scholar 

  106. Delobel-Ayoub M, Arnaud C, White-Koning M, EPIPAGE Study Group et al (2009) Behavioral problems and cognitive performance at 5 years of age after very preterm birth: the EPIPAGE Study. Pediatrics 123:1485–1492

    Article  PubMed  Google Scholar 

  107. Nalli C, Iodice A, Andreoli L et al (2014) The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus 23:507–517

    Article  CAS  PubMed  Google Scholar 

  108. Andreoli L, Fredi M, Nalli C et al (2012) Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 38:J197–J208

    Article  CAS  PubMed  Google Scholar 

  109. Carvalheiras G, Faria R, Braga J, Vasconcelos C (2012) Fetal outcome in autoimmune diseases. Autoimmun Rev 11:A520–A530

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, A-8036, Graz, Austria

    Karoline Mayer-Pickel, Uwe Lang & Mila Cervar-Zivkovic

  2. Research Facility for Biostatistics, Medical University of Graz, Graz, Austria

    Katharina Eberhard

Authors
  1. Karoline Mayer-Pickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katharina Eberhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uwe Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mila Cervar-Zivkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karoline Mayer-Pickel.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Funding

No funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayer-Pickel, K., Eberhard, K., Lang, U. et al. Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy. Clinic Rev Allerg Immunol 53, 54–67 (2017). https://doi.org/10.1007/s12016-016-8569-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8569-0

Keywords

Search

Navigation